ABSTRACT. We evaluated the diagnostic significance of the N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration in asymptomatic cats with cardiac enlargement. The plasma NT-proBNP concentration was measured in 21 clinically healthy control cats, and 67 asymptomatic cats with cardiac enlargement defined as end-diastolic interventricular septum thickness (IVSd) and/or diastolic left ventricular posterior wall thickness (LVPWd) >0.6 cm, vertebla heart scale (VHS) >7.8, and/or left atria/aorta ratio (LA/Ao) >1.5. The plasma NT-proBNP concentration in the asymptomatic cats with cardiac enlargement (median: 662.0, range: 24.0-2,449.0 pmol/l) was significantly higher than that in the controls (24.0, 24.0-95.0 pmol/l, P<0.001). The plasma NT-proBNP concentration was significantly correlated with the VHS, LA/Ao, IVSd and LVPWd (r=0.578, P<0.001; r=0.462, P<0.001; r=0.563, P<0.001; and r=0.764, P<0.001, respectively). Receiver operating characteristic analysis showed a cut-off value of 95.0 pmol/l for the detection of asymptomatic cats with cardiac enlargement, sensitivity and specificity of 88.1 and 100%, respectively, and an area under the curve of 0.971. These results suggest that the determination of the plasma NT-proBNP concentration can be a useful screening test for asymptomatic cats with cardiac enlargement.
The common causes of cardiac enlargement in cats include hypertrophic cardiomyopathy (HCM), hyperthyroidism and systemic hypertension. In advanced HCM, severe dyspnea due to pulmonary edema or pleural effusion, or acute bilateral paralysis of the hind limb resulting from arterial thromboembolism is often present. In contrast, such a drastic symptom was not observed in cats with asymptomatic HCM. Cardiac murmur due to outflow obstruction or systolic anterior motion (SAM) of the mitral valve is not always heard in cats with asymptomatic HCM [4, 16, 17] . The ability of thoracic radiography to detect ventricular hypertrophy is very low [12, 17] . In addition, echocardiography may not be actively performed in cats without any clinical sign related to cardiac enlargement. In general practice, asymptomatic enlargement of the heart might be also missed in cats with hyperthyroidism or systemic hypertension. Therefore, tools facilitating the detection of asymptomatic cats with cardiac enlargement are necessary.
B-type natriuretic peptide (BNP) is a hormone synthesized in the heart. Signal peptides are removed from peptides synthesized as prepro-BNP mainly in the ventricle, forming pro-BNP. This is cleaved into BNP and N-terminal pro-BNP (NT-proBNP), and then released into the circulation. BNP exhibits various physiological actions including natriuresis and inhibition of the renin-angiotensin system, whereas NT-proBNP does not show any physiological actions [6, 18] .
In humans with HCM, the plasma NT-proBNP concentration has been reported to be significantly associated with the severity of heart failure, left atrial size, the degree of ventricular diastolic dysfunction and left ventricular hypertrophy, and pressure gradient between the aorta and left ventricle [1, 11] . Furthermore, one human study reported that the plasma NT-proBNP concentration had high specificity for asymptomatic left ventricular dysfunction [2] . Thus, the plasma NT-proBNP concentration is an important parameter in the evaluation of the severity of heart failure, prognostic factors and treatment response in humans [1, 7] .
Recently, determination of the plasma NT-proBNP concentration in cats became possible, and the usefulness of this marker in cats with heart disease has been studied [5, 8] . However, there have been no studies on the diagnostic importance of the plasma NT-proBNP concentration in asymptomatic cats with cardiac enlargement to our knowledge. Therefore, we evaluated the diagnostic importance of the plasma NT-proBNP concentration in asymptomatic cats with cardiac enlargement.
MATERIALS AND METHODS
In the present study, 88 cats presented to 1 private clinic and 1 university hospital in Japan between February 2004 and April 2010 were used. Of these, 21 (8 males, 4 castrated males, 6 females and 3 spayed females) with a mean age of 6.0 (0.6-13.8) years were clinically healthy, showing no echocardiographic abnormalities, and assigned into the control group. These cats included 18 [9] , and assigned into the test group. Tables 1 and 2 show clinical profiles of both groups and current medication in the test group, respectively. In this study, cardiac enlargement was defined as a diastolic interventricular septum thickness (IVSd) and/or diastolic left ventricular posterior wall thickness (LVPWd) >0.6 cm, left atria/aorta ratio (LA/Ao) >1.5 on echocardiograms [11, 13] , and/or vertebra heart scale (VHS) >7.8 on right lateral thoracic X-ray images [15] . Echocardiography was performed in all cats under a conscious state. LA/Ao, diastolic left ventricular internal dimension (LVIDd), IVSd and LVPWd were measured using the right parasternal short axis view. VHS was measured in the control group (n=19, 90.5%) and the test group (n=67, 100%), respectively.
Blood was collected via the jugular vein, cephalic vein or saphenous vein, mixed with ethylenediaminetetraacetate (EDTA), stand at 4C for 30 min, and centrifuged (1,500 g, 10 min). Then, the plasma was separated and stored at -20C until measurement. The plasma NT-proBNP concentration was determined using the sandwich ELISA method developed for the measurement of feline plasma NTproBNP (Cardiopet TM proBNP, IDEXX Laboratories, Westbrook, ME, U.S.A.). This kit uses a purified sheep antibody with affinity specific to 2 sites of the feline NT-proBNP. The anti-NT-proBNP capture antibody (25-41) has been immobilized in each well of the plate, and the tracer includes anti-NT-proBNP (1-22) bound to horseradish peroxidase as a detection antibody. All procedures were performed according to the manufacturer's manual. Briefly, the frozen-dried standard solution was dissolved in 0.3 ml distilled water and left at room temperature for 30 min. Each standard solution and sample (20 l each) were added to each well, and the tracer (200 l) was added to all wells. After incubation in the dark at room temperature overnight (16-24 hr), the wells were washed with diluted washing buffer. All remaining washing buffer was removed, and the substrate (200 l) was added to all wells and thoroughly mixed. The plates were incubated in the dark at room temperature for 30 min. Subsequently, stop solution (50 l) was added to all wells, and absorbance was measured at 450 nm immediately.
Since the lower measurement limit using this kit was 24 pmol/l, concentrations lower than this value were regarded as 24 pmol/l for statistical analysis. Kolmogorov-Smirnov test was used to determine normal distribution. All measurements are expressed as the median value (range). Each variable of the both groups were compared using the MannWhitney U test. The correlation between the plasma NTproBNP concentration and each variable obtained by echocardiogram was analyzed using Pearson's correlation coefficient and linear regression analysis. P<0.05 was regarded as significant. The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic accuracy of the plasma NT-proBNP concentration to detect asymptomatic cats with cardiac enlargement and establish the cut-off value. All statistical analyses and the production of ROC curves were performed using a commercially available statistical software package (Dr. SPSSII for Windows, Version 11.0, 1J, SPSS Japan, Inc., Tokyo, Japan).
RESULTS
The plasma NT-proBNP concentration in the test group ( Fig. 1) . Table 3 Fig. 2A-D) but not with LVIDd (r= -0.049, P=0.648, not shown). ROC analysis showed an NT-proBNP cut-off value of 95.0 pmol/l and a sensitivity and specificity of 88.1 and 100%, respectively. The area under the curve was 0.971 (Fig. 3) .
DISCUSSION
HCM, hyperthyroidism and systemic hypertension are the examples of the most common disease in cats, and they could induce cardiac enlargement such as left atrial dilation and left ventricular hypertrophy. However, the detection of asymptomatic cats with cardiac enlargement will be difficult, because no cardiac disease is suspected, and echocardiography is not always performed in asymptomatic cases. This situation would indicate that the reliable tools to detect asymptomatic enlargement of the heart as a screening test was required in cat.
In the present study, the plasma NT-proBNP concentration in the test group was significantly higher than that in the control group, and the analysis of ROC curve revealed that the sensitivity and specificity would be clinically applicable. Thus, the use of the plasma NT-proBNP concentration as the screening test for cats was facilitated the detection of cardiac enlargement without clinical sign, and would be useful to determine whether ehocardiography is required.
Volume over loading on the atria and ventricle reflected by VHS and LA/Ao are considered to stimulate the production and secretion of BNP [6] . The plasma NT-proBNP concentration was significantly correlated with VHS and LA/Ao in the present study. This finding indicated that the plasma NT-proBNP concentration could detect even asymptomatic cats with cardiac enlargement.
The plasma NT-proBNP concentration did not correlated with LVIDd in the present study, the reasons(s) for this finding could not be clear in the present study. The results from further study including many cats with severer left ventricular dilation might explain this finding.
It is noteworthy that the plasma NT-proBNP concentration also significantly correlated with IVSd and LVPWd. This finding might suggest that the synthesis and secretion of proBNP in the cardiocyte were also stimulated by ventricular hypertrophy in addition to ventricular dilation. A previous study conducted in humans suggested that BNP was expressed in the ventricular myocytes of HCM with normal systolic function, and that ventricular BNP expression might be stimulated in response to obstruction and diastolic dysfunction [2] . These findings might indicate that asymptomatic ventricular hypertrophy could also be detected by the plasma NT-proBNP concentration. Biondo et al. reported that novel expression of BNP in the ventricular myocytes was observed in cats with HCM [3] . This might support significant correlation of the plasma NTproBNP concentration with IVSd and LVPWd observed in our study.
In conclusion, the present study indicated that measure- ment of plasma NT-proBNP concentration was reliable as the screening test to detect asymptomatic cats with cardiac enlargement. There are two limitations in the present study. First, the renal function of the cats was not evaluated in the present study. NT-proBNP in the plasma is considered to be excreted by the kidneys, and its concentration has been reported to be affected by renal function [14] . Therefore, further studies are necessary to evaluate the association between the plasma NT-proBNP concentration and renal function in cats. Second, a high degree of intra-individual variability of the plasma NT-proBNP concentration was observed in dogs [10] . In this study, the blood collection time was not the same. In addition, the influences of the age and sex on the plasma NT-proBNP concentration were not considered in our study. The diagnostic importance of the plasma NT-proBNP concentration may be further clarified by resolving these limitations. curve of the plasma NT-proBNP concentration.
